Platinum therapy resistance is associated with an enrichment of tumour angiogenesis in epithelial ovarian cancer
- The clinical and pre-clinical data discussed has potentially significant clinical implications in the management of treatment-relapsed HGSOC.
Platinum-resistance in relapsed HGSOC is an indicator for response to antiangiogenic agents.
- The novel identification of chemotherapy-mediated selection for an angiogenic phenotype in EOC, through upregulation of the PDGFR-VEGF-A signaling pathway.
- Targeted inhibition of PDGFR (using TKI or siRNA knockdown) reverses platinum therapy resistance in EOC.
- This clinical and pre-clinical data supports the use of anti-angiogenic agents in the first and second line setting in patients with innate and acquired resistance to platinum therapy, respectively.
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.